L Wang, Q Yang, Q Zhou, F Fang, K Lei, Z Liu, G Zheng… - Cancer letters, 2023 - Elsevier
Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular
carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy …